Abstract
MONALEESA (ML)-2 and -7 enrolled postmenopausal (postM) and premenopausal (preM) patients (pts) with HR+/HER2− ABC, respectively, to initial RIB + ET treatment. Both demonstrated a statistically significant PFS and OS benefit in the ITT populations, with similar trends in the Asian subgroups. Specifically, regarding PFS in the Asian subgroups, RIB + ET had an HR of 0.39 (0.17-0.91) in ML-2 (n=51; median follow-up 15.3 mo) and ET had an HR of 0.40 (0.26-0.63) in ML-7 (n=198; median follow-up 19.2 mo).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
